相关实验视频

Updated: Jun 15, 2025

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Published on: June 18, 2015

在临床相关的低度下,C188-9可降低患者特异性原发性乳腺癌细胞的增殖

Rongji Zheng¹, Tian Guan², Chaoqun Hong¹

¹The Breast Center, Cancer Hospital of Shantou University Medical College, 7 Raoping Rd, Shantou, Guangdong, 515000, China.

Journal of translational medicine

|August 22, 2024

概括

通过降低癌细胞活力,STAT3抑制剂C188-9在治疗乳腺癌方面表现有前途. 这种新型药物在患者特异性初级细胞 (PSPC) 中表现出有效性,这表明了个性化癌症治疗的潜力.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
药理学药理学是指药理学的学科.

背景情况:

信号传感器和转录3激活器 (STAT3) 是乳腺癌瘤基因的一个关键的转录激活器.
在乳腺癌治疗中,STAT3是潜在的治疗点.
患者特异性原始细胞 (PSPCs) 为临床前药物评估提供了一个新的平台.

研究的目的:

研究C188-9的治疗潜力,一种STAT3信号通路抑制剂,用于乳腺癌治疗.
为了评估C188-9的疗效,使用与PSPCs一起的临床前平台.
为了比较C188-9与传统化疗剂的有效性.

主要方法:

从15个乳腺癌患者样本中分离出PSPC.
用C188-9 (实验和临床相关度) 和其他化疗剂治疗PSPC.
使用细胞活力测定,西斑和实时定量PCR来评估药物效应和STAT3通路活性.

主要成果:

在实验度下,C188-9显著抑制了PSPC的扩散.
在临床相关的低度下,C188-9比一些传统的化疗药物更有效地降低了PSPC活力.
C188-9降低了PSPCs的一个子集中的pSTAT3表达,并抑制了STAT3到C-myc信号通路.

结论:

C188-9在十五名患者中的十名的PSPC中显示出治疗效果,而一些传统药物无效.
该研究强调了C188-9在基于PSPC敏感性的乳腺癌治疗中的潜在个性化应用.
这项研究强调了PSPCs在预测药物反应和指导个性化瘤战略方面的价值.

关键词:

乳腺癌是什么? 乳腺癌是什么在C188-9中,你会看到.公共服务保险公司 (PSPCs) 提供服务.在STAT3中,我们可以使用STAT3.

更多相关视频

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

Utilization of the Soft Agar Colony Formation Assay to Identify Inhibitors of Tumorigenicity in Breast Cancer Cells

Utilization of the Soft Agar Colony Formation Assay to Identify Inhibitors of Tumorigenicity in Breast Cancer Cells

Published on: May 20, 2015

相关概念视频

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...